Andrea Bieser

NICE (National Institute for Health and Clinical Excellence) reviews the cost effectiveness of medicines for the treatment of multiple sclerosis (annual cost per patient €10,000-18,000) and does not authorize their use within the UK National Health Service. However, an agreement between the manufacturers and the Department of Health is reached on an innovative risk sharing scheme.

Published 07 Jan 2006

Reference 5381

Topic Marketing

Industry Pharmaceuticals

Region Europe

View case